Put companies on watchlist
Ikonisys SA
ISIN: FR00140048X2
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Ikonisys SA · ISIN: FR00140048X2 · EQS - Analysts (14 News)
Country: Germany · Primary market: France · EQS NID: 17421
31 July 2023 07:56AM

Ikonisys SA (von Sphene Capital GmbH): Buy

Original-Research: Ikonisys SA - von Sphene Capital GmbH

Einstufung von Sphene Capital GmbH zu Ikonisys SA

Unternehmen: Ikonisys SA
ISIN: FR00140048X2

Anlass der Studie: Update Report
Empfehlung: Buy
seit: 31.07.2023
Kursziel: EUR 4,50 (unverändert)
Kursziel auf Sicht von: 36 Monate
Letzte Ratingänderung: -
Analyst: Peter Thilo Hasler, CEFA

Second sale of the high-volume Ikoniscope20max  
With another sale completed of the Ikonicope20max, the high-end, high-volume configuration of the Ikoniscope20 for high-throughput laboratories, we believe Ikonisys is on track to expand its global reach and to meet our long-term financial targets. We are confirming our Buy rating for the shares of Ikonisys SA and our price target of EUR 4.50 which is based on a three-stage DCF entity model (base case scenario). In a Monte Carlo analysis we used alternative sales and earnings scenarios and calculated equity values in a range between EUR 45.1m (10% quantile) and EUR 67.6m (90% quantile), which translate into price targets between EUR 3.50 and EUR 5.30 per share.

Ikonisys announced the second sale and installation of the Ikoniscope20max; the customer is a specialized urology laboratory in the Midwestern United States. The Ikoniscope20max is a high-volume configuration of the Ikoniscope20 specifically designed for high-throughput medium and large laboratories.

The sale highlights the strong value proposition of the Ikoniscope20 for laboratories, where we believe Ikonisys has taken a technology leadership position in laboratory automation, ahead of larger competitors such as Olympus, Leica, Thermo Fisher, Perkin Elmer, Applied Spectral Imaging, Bioview, MetaSystems or Zeiss, none of which have achieved such a deep level of automation as Ikonisys, in our view.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/27421.pdf

Kontakt für Rückfragen
Peter Thilo Hasler, CEFA
+49 (89) 74443558/ +49 (152) 31764553

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

Visual performance / price development - Ikonisys SA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.

The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.

1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.